1. <optgroup id="wrmvh"><li id="wrmvh"><center id="wrmvh"></center></li></optgroup>
    <cite id="wrmvh"><li id="wrmvh"><center id="wrmvh"></center></li></cite>
      1. <legend id="wrmvh"></legend>

        <ol id="wrmvh"></ol>

          1. <strong id="wrmvh"></strong>
          2. <legend id="wrmvh"><i id="wrmvh"></i></legend>
            <optgroup id="wrmvh"></optgroup>
            <legend id="wrmvh"><i id="wrmvh"></i></legend>
            <span id="wrmvh"><sup id="wrmvh"><object id="wrmvh"></object></sup></span>
            1. <span id="wrmvh"><video id="wrmvh"></video></span>
              <sub id="wrmvh"><sup id="wrmvh"></sup></sub>
              <strong id="wrmvh"></strong>
              <legend id="wrmvh"><i id="wrmvh"></i></legend>
              1. <sub id="wrmvh"><sup id="wrmvh"></sup></sub>
                1.  
                   
                   
                   
                   
                  專職PI
                  楊恭 研究員
                  研究員,博士生導師
                  E-mail: yanggong@fudan.edu.cn
                   

                    2001年畢業于中國科學院微生物研究所,獲得博士學位。2001年至2005年先后在美國休斯敦霍華德·休斯醫學研究所、美國M.D. Anderson腫瘤中心從事博士后研究工作。2005年任美國德克薩斯大學M.D. Anderson癌癥研究中心病理系講師,并于2008年升職為美國德克薩斯大學M.D. Anderson癌癥研究中心病理系助理教授。2010年回國工作,擔任復旦大學附屬腫瘤醫院研究所研究員,博士生導師,實驗研究中心/研究所副主任。20126-8月作為客座教授在日本金沢大學癌癥研究所工作。2013年至今,任復旦大學附屬腫瘤醫院研究所研究員,博士生導師婦科腫瘤/腫瘤化療研究課題組長/PI;復旦大學附屬上海市第五人民醫院特聘教授,博士生導師,中心實驗室常務副主任,組織樣本庫/慢性病平臺負責人。

                        楊恭教授目前在JNCI、PNAS、Clin Cancer Res、JBC、Cancer Res、Theranotics、Molecular Therapy、Oncogene、Cancer letter、European Journal of Cancer、International Journal of Cancer等國際知名雜志上發表SCI論文近70余篇。主持國家自然科學基金/重大研發計劃5項,教育部博士點基金博導類1項;上海市浦江人才計劃1項;上海市衛生局局級基金2項;參與科技部重大研發計劃(子課題)精準醫學項目 1項,重大慢性非傳染性疾病項目(子課題)1項。


                  研究領域:

                    1. 腫瘤微環境IL-8ECM1促進腫瘤轉移復發、干細胞分化和化療抵抗的機制;
                    2. 細胞永生化與轉化動物模型構建及分析;
                    3. 細胞衰老與惡性轉化;
                    4. RAS/P53相關基因突變與細胞凋亡、衰老以及EMT、自噬的關系;
                    5. 腫瘤靶向藥物的篩選與開發;
                    6. DNA損傷修復與腫瘤放化療抵抗及其與腫瘤干細胞調控的機制。


                  研究團隊:

                    現有研究助理1名,技術員1名,研究生7名。


                  代表性論著:

                  1. Yang Shao, Xiaomin Liu, Jiao Meng, Xiaofei Zhang, Zhongliang Ma, Gong Yang*. MicroRNA-1251-5p Promotes Carcinogenesis and Autophagy via Targeting the Tumor Suppressor TBCC in Ovarian Cancer Cells. Molecular Therapy, 2019 Sep; 27(9):1653-64.
                  2. Xiaofei Zhang, Zihao Qi, Huijing Yin, Gong Yang*. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy. Theranostics,2019; 9(4):1096-114.
                  3. Fan Liang, Chunxia Ren, Jingshu Wang, Shuoer Wang, Lina Yang, Xianghui Han, Yaping Chen, Guoqing Tong, Gong Yang*. The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy. Oncogenesis, 2019; 8(10):59.
                  4. Jingshu Wang, Lina Yang, Fan Liang, Yaping Chen, Gong Yang*. ITGAX stimulates cancer angiogenesis through PI3K/Akt signaling–mediated VEGFR2/VEGF‐A overexpression in blood vessel endothelial cells. J Cell Biochem, 2019; 120(2):1807-1818.
                  5. Bin Chang, Jiao Meng, Huimin Zhu, Xiang Du, Lili Sun, Lei Wang, Shugang Li, Gong Yang*. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma. Diagnostic Pathology2018 Nov 14; 13(1):87.
                  6. Han Xu, Fengjuan Lin, Ziliang Wang, Lina Yang, Jiao Meng, Zhouluo Ou, Zhimin Shao, Genhong Di, Gong Yang*. CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2. Cancer Letters, 2018; 412:69-80.
                  7. Zhang X, Wang S, Zhao S, Sun Y, Yang G*. Postoperative chemotherapy had no prognostic effect on early-staged young ovarian cancer with unilateral resection. Cancer Med, 2018 Nov; 7(11):5488-5496.
                  8. Shao Y, Li H, Du R, Meng J, Yang G*. Involvement of non-coding RNAs in chemotherapy resistance of ovarian cancer. J Cancer, 2018 Apr 30; 9(11):1966-1972.
                  9. Chang B, Meng J, Zhu H, Du X, Sun L, Wang L, Li S, Yang G*.Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma. Diagnostic Pathology, 2018 Nov 14;13(1):87. doi: 10.1186/s13000-018-0754-4.
                  10. Xiang L, Jiang W, Ye S, He T, Pei X, Li J, Chan DW, Ngan HYS, Li F, Tao P, Shen X, Zhou X, Wu X, Yang G*, Yang H. ERBB2 mutation: A promising target in non-squamous cervical cancer. Gynecol Oncol, 2018 Feb;148(2):311-316.
                  11. Shuqing Li, Lina Yang, Jingshu Wang, Fan Liang, Bin Chang, Huafen Gu, Honglin Wang, Yang Gong*, Yaping Chen. Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells. Oncotarget, 2017; 7(35):57145-57159.
                  12. Zhang X, Cheng Q, Yin H and Yang G*. Regulation of autophagy and EMT by the interplay between p53 and RAS during cancer progression. Int J Oncol, 2017; 51:18-24.
                  13. Shuwen Yang, Qinghai Ji, Bin Chang, Yan Wang, Yongxue Zhu, Duanshu Li, Caiping Huang, Yulong Wang, Guohua Sun, Ling Zhang, Qing Guan, Jun Xiang, Wenjun Wei, Zhongwu Lu, Tian Liao, Jiao Meng, Ziliang Wang, Ben Ma, Li Zhou, Yu Wang, Gong Yang*. STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling. Oncotarget, 2017; 8(4):5976-5991.
                  14. Lu L, Wang J, Wu Y, Wang P, Yang G*. Rap1A promotes ovarian cancer metastasis via activation of ERK/p38 and notch signaling. Cancer Medicine, 2016; 5(12):3544–3554.
                  15. Xiao X, Yang G#, Bai P, Gui S, Nyuyen TM, Mercado-Uribe I, Yang M, Zou J, Li Q, Xiao J, Chang B, Liu G, Wang H, Liu J. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway. BMC Cancer, 2016 Aug 2;16:582.
                  16. Yin S, Wang P, Yang L, Liu Y, Wang Y, Liu M, Qi Z, Meng J, Shi T, Yang G*, Zang R. Wip1 suppresses ovarian cancer metastasis through the ATM/AKT/Snail mediated signaling. Oncotarget, 2016; 7(20):29359-29370.
                  17. Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G*, Wang J, Lu J. MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells. Oncotarget, 2016; 7(17):24537-24548.
                  18. Li Y, Zhou J, Wu Y, Lu T, Yuan M, Cui Y, Zhou Y, Yang G*, Hong Y. Association of osteoporosis with geneticvariants of circadiangenes in Chinesegeriatrics. OsteoporosInt, 2016 Apr; 27(4):1485-92.
                  19. Zhou J, Li Y, Yang L, Wu Y, Zhou Y, Cui Y, Yang G*, Hong Y. Stanniocalcin 2 improves osteoblast differentiation via phosphorylation of ERK. Mol Med Rep, 2016 Dec;14(6):5653-5659.
                  20. Wu Y, Zhou J, Li Y, Zhou Y, Cui Y, Yang G*, Hong Y. Rap1A Regulates Osteoblastic Differentiation via the ERK and p38 Mediated Signaling. PLoS One, 2015 Nov 24; 10(11):e0143777.
                  21. Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G*, Zhang Q. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway. Oncotarget, 2015 Sep 22; 6(28): 25281-25294.
                  22. Xiang L, Jiang W, Li J, Shen X, Yang W, Yang G*, Wu X, Yang H. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer. Sci Rep, 2015 Sep 11; 5:14035.
                  23. Sun JM, Yang LN, Xu H, Chang B, Wang HY, Yang G*. Inhibition of Aurora A promotes chemosensitivity via inducing cell cycle arrest and apoptosis in cervical cancer cells. Am J Cancer Res, 2015 Feb 15; 5(3):1133-1145.
                  24. Qiu JJ, Wang Y, Ding JX, Jin HY, Yang G, Hua KQ. The long non-coding RNA HOTAIR promotes the proliferation of serous ovarian cancer cells through the regulation of cell cycle arrest and apoptosis. Exp Cell Res, 2015 May 1; 333(2):238-48.
                  25. Hou J, Wang Z, Xu H, Yang L, Yu X, Yang Z, Deng Y, Meng J, Feng Y, Guo X, Yang G.* Stanniocalicin 2 Suppresses Breast Cancer Cell Migration and Invasion via the PKC/ Claudin-1-Mediated Signaling. PLoS One, 2015 Apr 1; 10(4):e0122179.
                  26. Yang L, Shi T, Liu F, Ren C, Wang Z, Li Y, Tu X, Yang G*, Cheng X. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells. PLoS One, 2015 Mar 17; 10(3):e0120334.
                  27. Wang Z, Liu Y, Lu L, Yang L, Yin S, Wang Y, Qi Z, Meng J, Zang R, Yang G*. Fibrillin-1, induced by Aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget, 2015 Mar 30; 6(9): 6670-83.
                  28. Yang L, Zhou Y, Wu Y, Cui Y, Yang G*, Hong Y. p53 deficiency and KRAS mutation synergistically activate NF-kB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Cancer Lett, 2015 Feb 28; 357(2):520-6.
                  29. Qi Z, Liu M, Liu Y, Zhang M, Yang G*. Tetramethoxychalcone, a chalcone derivative, suppresses proliferation, blocks cell cycle progression, and induces apoptosis of human ovarian cancer cells. Plos One, 2014 Sep 2; 9(9):e106206.
                  30. Wang Z, Liu Y, Yang L, Yin S, Zang R, Yang G*. The polymorphism interleukin-8 -251A/T is associated with a significantly increased risk of cancers from a meta-analysis. TumourBiol, 2014 Jul; 35(7):7115-23.
                  31. Qian Y, Wang Y, Ji Q, Yang G*. The chemokine receptor- CXCR2 plays a critical role in the invasion and metastasis of oral squamous cell carcinoma in vitro and in vivo. J Oral Pathol Med, 2014 Oct; 43(9):658-66.
                  32. Hou J, Wang Z, Yang L, Guo X, Yang G*. The function of EMSY in cancer development. Tumour Biol, 2014 Jun; 35(6):5061-6.
                  33. Wang Y, Wang Z, Qi Z, Yin S, Zhang N, Liu Y, Liu M, Meng J, Zang R, Zhang Z, Yang G*. The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy. Mol Cancer, 2014 Apr 28; 13:94.
                  34. Sun H, Wang Y, Wang Z, Meng J, Qi Z, Yang G*. Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks. BiochimBiophysActa (Molecular Cell Research), 2014 May; 1843(5):934-44.
                  35. Wang Y, Sun H, Wang Z, Liu M, Qi Z, Meng J, Sun J, Yang G*. Aurora-A: a potential DNA repair modulator. TumourBiol, 2014 Apr; 35(4):2831-6.
                  36. Chen Y, Ke G, Han D, Liang S, Yang G, Wu X. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD. Exp Cell Res, 2014 Jan 1; 320(1):12-20.
                  37. Wang Z, Hou J, Lu L, Qi Z, Sun J, Gao W, Meng J, Wang Y, Sun H, Gu H, Xin Y, Guo X, Yang G*. Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways. PLoS One, 2013 Nov 11; 8(11):e79117.
                  38. Ren C, Cheng X, Lu B, Yang G*. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. Eur J Cancer, 2013 Dec; 49(18):3889-99.
                  39. Lin F, Luo J, Gao W, Wu J, Shao Z, Wang Z, Meng J, Ou Z, Yang G*. COX-2 promotes breast cancer cell radioresistance via p38/MAPK-mediated cellular anti-apoptosis and invasiveness. TumourBiol, 2013 Oct; 34(5):2817-26.
                  40. Yang G*#, Mercado-Uribe I, Multani AS, Sen S, Shih IM, Wong KK, Gershenson DM, Liu J. RAS Promotes Tumorigenesis through Genomic Instability Induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer, 2013 Jul 15; 133(2):275-285.
                  41. Shi TY, Yang L, Yang G, Tu XY, Wu X, Cheng X, Wei Q. DNA polymerase ζ as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer. Med Oncol, 2013 Jun; 30(2):500.
                  42. Shi TY, Yang G, Tu XY, Yang JM, Qian J, Wu XH, Zhou XY, Cheng X, Wei Q. RAD52 variants predict platinum resistance and prognosis of cervical cancer. PLoS One, 2012; 7(11):e50461.
                  43. Guo X, Liu G, Schauer, IG, Yang G, Mercado-Uribe,I, Yang F, Zhang,S, He Y, Liu J, Over-expression of the beta subunit of human chorionic gonadotropin promotes the transformation of human ovarian epithelial cells and ovarian tumorigenesis. Am J Pathol, 2011 Sep; 179(3): 1385-93.
                  44. Yang F, Guo X, Yang G, Rosen DG and Liu J. AURKA and BRCA2 expression highly correlate with prognosis of endometrioid ovarian carcinoma. Modern Pathology, 2011 Jun; 24(6):836-45.
                  45. Yang G#, Xiao X, Rosen DG, Cheng X, Wu X, Chang B, Liu G, Xue F, Mercado- Uribe I, Chiao PJ, Du X, Liu J. The Biphasic Role of NF-{kappa}B in Tumor Progression and Chemoresistance of Ovarian Cancer. Clin Cancer Res, 2011 Apr 15; 17(8):2181-94.
                  46. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, Liu J, Kavanagh JJ. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy.GynecolOncol, 2011 May 1; 121(2):323-7.
                  47. Yang G#, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J.CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res, 2010 Aug 1; 16(15):3875-86.
                  48. Liu G#, Yang G#, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst, 2010 Jun 2; 102(11):812-27.
                  49. Yang G#, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res, 2010 Jun 15; 16(12):3171-81.
                  50. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Noara H, Auersperg N, Mills GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle, 2010 Jan 1; 9(1):140-6.
                  51. Xiao X, Bai P, Bui Nguyen TM, Xiao J, Liu S, Yang G, Hu L, Chen X, Zhang X, Liu J, Wang H. The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther, 2009 May; 8(5):1179-88.
                  52. Shan W, Yang G, Liu J. The inflammatory network: bridging senescent stroma and epithelial tumorigenesis. Front Biosci, 2009 Jan 1; 14:4044-57.
                  53. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao XS, Zheng J, Xue FX, Liu J. Ovarian cancer: pathology, biology, and disease models. Front Biosci, 2009 Jan 1; 14:2089-102.
                  54. Chang B, Liu G, Yang G, Mercado-Uribe I, Huang M, Liu J. REDD1 is required for RAS-mediated transformation of human ovarian epithelial cells. Cell Cycle, 2009 Mar 1; 8(5):780-6.
                  55. Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther, 2008 Jul; 7 (7):1993-2002.
                  56. Zhang Z, Singh M, Davidson S, Rosen DG, Yang G, Liu J. Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries. Mod Pathol, 2007 Oct; 20(10):1078-84.
                  57. Yang G#, Rosen DG, Colacino JA, Mercado-Uribe I, Liu J.Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells. Oncogene, 2007 Mar 1; 26(10): 1492-8.
                  58. Young TW, Mei FC, Rosen DG, Yang G, Li N, Liu J, Cheng X. Up-regulation of Tumor Susceptibility Gene 101 Protein in Ovarian Carcinomas Revealed by Proteomics Analyses. Mol Cell Proteomics, 2007 Feb; 6(2): 294-304.
                  59. Yang G#, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC Jr, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis, 2007 Jan; 28(1): 174-82.
                  60. Rosen DG, Mercado-Uribe I, Yang G, Bast RC Jr, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 2006 Dec 1; 107(11): 2730-40.
                  61. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene, 2006 Nov 2; 25(52): 6986-96.
                  62. Rosen DG#, Yang G#, Bast RC Jr, Liu J.Use of ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol, 2006; 407: 660-76.
                  63. Yang G#, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I, Liu J.The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A, 2006 Oct 31; 103(44): 16472-7.
                  64. Rosen DG,Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J.Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer, 2006 May 1; 106(9): 1925-32.
                  65. Hu Y, Rosen DG, Zhou Y, Feng L, Yang G, Liu J, Huang P.Mitochondrial manganese-superoxide dismutase expression in ovarian cancer: role in cell proliferation and response to oxidative stress. J BiolChem, 2005 Nov 25; 280(47): 39485-92.
                  66. Rosen DG,Yang G, Cai KQ, Bast RC Jr, Gershenson DM, Silva EG, Liu J.Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res, 2005 Jan 15; 11(2 Pt 1): 632-7.
                  67. Young TW, Mei FC,Yang G, Thompson-Lanza JA, Liu J, Cheng X.Activation of antioxidant pathways in ras-mediated oncogenic transformation of human surface ovarian epithelial cells revealed by functional proteomics and mass spectrometry. Cancer Res, 2004 Jul 1; 64(13): 4577-84.
                   
                  復旦大學腫瘤研究所 通訊地址: 東安路270號2號樓1312室 64175590-5312 Email:fuci2012@126.com
                  Copyright 2013 shca.org.cn All rights reserved. 復旦大學腫瘤研究所 版權所有
                  小草在线观看视频播放免费 75tty小草社区| 丝瓜视频成年版app下载| 青青国产精品在线手机视频| 全免费观看三级| 九九99线视频在线观看| 樱桃在线福利直播| 快看影院在线手机版下载 迅雷下载安装| 小草社区2018最新ip地址| 小草社区201| 静典千人斩官网| 飘花伊人官网 私人影视|